Oropharynx (p16-)

Primary Site Histology Schema Discriminator 1 Schema Discriminator 2
C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 8000-8700, 9700-9701 1, 9
C111 8000-8700, 9700-9701 2 1, 9

Notes

C019 Base of tongue, NOS C024 Lingual tonsil C051 Soft palate, NOS C052 Uvula C090 Tonsillar fossa C091 Tonsillar pillar C098 Overlapping lesion of tonsil C099 Tonsil, NOS C100 Vallecula C102 Lateral wall of oropharynx C103 Posterior wall of oropharynx C104 Branchial cleft (site of neoplasm) C108 Overlapping lesion of oropharynx C109 Oropharynx, NOS C111 Pharyngeal tonsil **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. If a case of oropharyngeal cancer has p16+, then this chapter is used. If a case does not have p16 or HPV by ISH, then the case is staged by the p16- system.

Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Year of Diagnosis <BLANK> No NAACCR #390 None
Primary Site <BLANK> Yes NAACCR #400 None
Histology <BLANK> Yes NAACCR #522 None
Behavior <BLANK> No NAACCR #523 None
Schema Discriminator 1 <BLANK> Yes NAACCR #3926 All SSDI
Schema Discriminator 2 9 Yes NAACCR #3927 All SSDI
Tumor Size Clinical <BLANK> No NAACCR #752 None
Tumor Size Pathological <BLANK> No NAACCR #754 None
Tumor Size Summary 999 Yes NAACCR #756 None
Regional Nodes Positive 99 No NAACCR #820 None
Regional Nodes Examined 99 No NAACCR #830 None
RX Summ Surgery/Radiation Sequence <BLANK> No NAACCR #1380 None
RX Summ Systemic/Surgery Sequence <BLANK> No NAACCR #1639 None
EOD Primary Tumor 999 Yes NAACCR #772 None
EOD Regional Nodes 999 Yes NAACCR #774 None
EOD Mets 00 Yes NAACCR #776 None
SS2018 <BLANK> No NAACCR #764 None
Grade Clinical 9 No NAACCR #3843 CCCR/Canada
COC
NPCR
SEER		 SSDI
Grade Pathological 9 No NAACCR #3844 CCCR/Canada
COC
NPCR
SEER		 SSDI
Grade Post Therapy <BLANK> No NAACCR #3845 CCCR/Canada
COC
NPCR
SEER		 SSDI
Extranodal Exten H&N Clin 8 No NAACCR #3831 COC
SEER		 SSDI
Extranodal Exten H&N Path X.8 No NAACCR #3832 CCCR/Canada
COC
SEER		 SSDI
Lymph Nodes Size of Mets XX.8 No NAACCR #3883 CCCR/Canada
COC
NPCR
SEER		 SSDI
SEER_SSF1: SEER Site-Specific Fact 1 9 No NAACCR #3700 SEER SSDI

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context
ss2018_derived = 90

Next Step

  2. EOD Primary Tumor
  3. ss2018_t

Next Step

  2. EOD Regional Nodes
  3. ss2018_n

Next Step

  2. EOD Mets
  3. ss2018_m

Next Step

  2. Summary Stage
  3. ss2018_derived

End

AJCC Chapter Calculation

Start

  2. AJCC Chapter Calculation
  3. ajcc_id

End

Outputs

Name Default Value Description NAACCR Item
Schema ID 00111 NAACCR #3800
AJCC ID XX NAACCR #995
Derived Version {{ctx_alg_version}} None
Derived Summary Stage 2018 9 NAACCR #762